bioAffinity Technologies, Inc.

Diagnostics company developing non-invasive sputum tests for early lung cancer

What bioAffinity does

bioAffinity Technologies develops lab tests that look for signs of lung cancer and other lung diseases without invasive procedures. Its CyPath Lung test uses flow cytometry and automated analysis to examine cells in a patient's sputum (phlegm) and flag features that point to lung cancer, including cancer-related cells shed from a tumor. The company also works with Brooke Army Medical Center on tests under development for asthma and COPD.

How bioAffinity makes money

The company earns revenue through its Laboratory Services segment, which performs diagnostic lab testing. Its Diagnostic Research and Development segment builds new tests it hopes to sell.

Products & services

• CyPath Lung
• Laboratory testing services
• Asthma inflammatory biomarker tests (in development)
• COPD inflammatory biomarker tests (in development)